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BACKGROUND Acute deterioration in renal function is a recognized complication after coronary angiography
and intervention.
OBJECTIVES The goal of this study was to determine the impact on acute and long-term mortality and
morbidity of contrast-induced deterioration in renal function after coronary intervention.
METHODS We studied 439 consecutive patients who had a baseline serum creatinine $1.8 mg/dL
(159.1 mmol/L) who were not on dialysis who underwent percutaneous coronary intervention
in a tertiary referral center. All patients were hydrated before the procedure, and almost all
received ioxaglate meglumine; 161 (37%) patients had an increase in serum creatinine $25%
within 48 h or required dialysis and 278 (63%) did not. In-hospital and out-of-hospital
clinical events (death, myocardial infarction, repeat revascularization) were assessed by source
documentation.
RESULTS Independent predictors of renal function deterioration were left ventricular ejection fraction
(p 5 0.02) and contrast volume (p 5 0.01). In-hospital mortality was 14.9% for patients with
further renal function deterioration versus 4.9% for patients with no creatinine increase (p 5
0.001); other complications were also more frequent. Thirty-one patients required hemodi-
alysis; their in-hospital mortality was 22.6%. Four patients were discharged on chronic
dialysis. The cumulative one-year mortality was 45.2% for those who required dialysis, 35.4%
for those who did not require dialysis and 19.4% for patients with no creatinine increase (p 5
0.001). Independent predictors of one-year mortality were creatinine elevation (p 5 0.0001),
age (p 5 0.03) and vein graft lesion location (p 5 0.08).
CONCLUSIONS For patients with pre-existing renal insufficiency, renal function deterioration after coronary
intervention is a marker for poor outcomes. This is especially true for patients who require
dialysis. (J Am Coll Cardiol 2000;36:1542–8) © 2000 by the American College of
Cardiology
Acute deterioration in renal function is a recognized com-
plication after coronary angiography, particularly for pa-
tients with pre-existing chronic renal insufficiency (CRI)
(1–4). Previous studies have shown that 12 to 14% of
patients who develop acute renal insufficiency during hos-
pitalization do so after procedures involving radiographic
contrast (5,6). For patients with abnormal baseline renal
function, the incidence of progressive deterioration can be as
high as 42% (1,7). For hospitalized, critically ill patients,
this carries a poor prognosis, especially if dialysis becomes
necessary (5–10).
The expanding use of diagnostic and therapeutic percu-
taneous interventions makes it important to understand the
potential risks involved with these procedures. The purpose
of this study was to review the in-hospital and long-term
clinical outcomes of 439 consecutive patients with impaired
baseline renal function who underwent percutaneous coro-
nary intervention and had significant deterioration in renal
function after the procedure.
METHODS
Patient population. The cohort is a consecutive series of
439 patients who had a baseline serum creatinine $1.8
mg/dL (159.1 mmol/L), but were not on dialysis, who
underwent percutaneous coronary intervention. Patients
were divided into two groups: 161 (37%) patients had an
increase in serum creatinine $25% within 48 h or required
dialysis (group 1) and 278 (63%) did not (group 2).
All patients underwent cardiac catheterization and inter-
vention by standard techniques. All patients received intra-
venous hydration before the procedure. Hydration included
0.5 normal saline solution at 75 ml/h to 100 ml/h for 6 to
12 h before the intervention and for 6 h after the interven-
tion. There was no formal protocol for use of periprocedural
diuretics or other potentially renal-protective agents. The
choice of radiocontrast material was left to the discretion of
the operating physician; however, in over 95% of cases an
ionic low osmolar contrast agent was used. Interventional
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treatment strategy (stents, rotational atherectomy, direc-
tional coronary atherectomy or excimer laser angioplasty)
was performed by the operator based on vessel size, coronary
anatomy and preprocedural lesion morphology. During the
procedure heparin was administered to achieve an activated
clotting time of approximately 300 s; heparin was not
continued routinely after the procedure unless there were
other indications for its use. Aspirin 325 mg was started at
least 24 h before the procedure and continued indefinitely.
After stent implantation patients received either ticlopidine
(250 mg orally twice a day for two to four weeks) or
clopidogrel (75 mg daily for two to four weeks). Other
medications (that is, nitrates, calcium channel antagonists,
etc.) were administered at the discretion of the operator.
Angiographic analysis. Quantitative angiographic analysis
was done at a dedicated Angiographic Core Laboratory by
observers who were unaware of the clinical data and purpose
of this study. Quantitative coronary angiographic analysis
was performed using automated edge-detection algorithm
(CMS, Medis Medical Imaging Systems, Ridgefield, Con-
necticut). Using the contrast filled catheter as the calibration
standard, minimal lumen diameters, reference diameter and
percent diameter stenosis before and after intervention were
measured from multiple projections, and the results from
the single “worst” and least foreshortened view were re-
corded. Standard qualitative morphologic criteria were tab-
ulated (11,12). Left ventricular ejection fraction was deter-
mined by ventriculography or by echocardiography.
Clinical definitions. Baseline laboratory values were ob-
tained for all patients upon admission. Creatinine clearance
(CrCl) was calculated by applying the Cockcroft-Gault
formula to the baseline serum creatinine: CrCl 5 ([140 2
age] 3 weight/serum creatinine 3 72) with female gender
adjustment (CrClfemale 5 CrCl 3 0.85) (13).
Procedural success was defined as ,50% residual diam-
eter stenosis and Thrombolysis In Myocardial Infarction
(TIMI) flow .grade 2 in the absence of major in-hospital
complications: death, MI or urgent bypass surgery (within
24 h after procedure). Q-wave MI was identified by the
presence of new Q-waves. Non-Q-wave MI was defined as
the elevation of creatine kinase-MB fraction $5 3 normal
without the appearance of new Q-waves.
Follow-up clinical events were assessed by serial tele-
phone interviews at 1, 3, 6, 12 months and yearly thereafter.
All events were source-documented including death, MI
and repeat intervention or bypass surgery as related to the
treated lesion.
Statistical analysis. Statistical analyses were performed
using SAS 6.10 (SAS Institute). Continuous variables were
presented as mean 6 1 standard deviation and were com-
pared using Student t test. Categorical variables were
presented as percentages and were compared using the
chi-square statistics or the Fisher exact test. Kaplan-Meier
survival curves were used to compare freedom from death
and late events (death, MI or revascularization). Multivar-
iate logistic regression analysis was used to determine
predictors of renal function deterioration. Cox proportion-
ate hazard model was used to determine predictors of late
mortality. A p value ,0.05 was considered statistically
significant. Odds ratios (OR) and 95% confidence intervals
(CI) are reported.
RESULTS
Patient characteristics and procedural variables. Patients
with postprocedural renal function deterioration (group 1)
were compared with patients with no increase in serum
creatinine (group 2). The group with renal function deteri-
oration included more diabetics and had worse left ventric-
ular function. Other clinical characteristics were similar
(Table 1).
Baseline serum creatinine was lower in group 1 (Table 2).
However, CrCl (estimated by the Cockcroft-Gault formula)
was similar for both groups, indicating no difference in
baseline renal function when age and body weight were
taken in account. The majority of the patients in both
groups received ioxaglate meglumine, an ionic low osmolar
contrast agent (Hexabrix, Mallinkrodt Medical Inc., St
Louis, Missouri), 93% versus 90%, p 5 NS. There was a
larger volume of contrast used in group 1 patients. Angio-
graphic analysis is shown in Table 3. There was a higher
frequency of saphenous vein graft lesions in group 1. This
was reflected in larger reference vessel size and larger final
minimal lumen diameter.
Predictors of renal function deterioration. The following
variables were entered into a multivariate model for
predicting renal function deterioration: age, left ventric-
ular ejection fraction, diabetes mellitus, hypertension,
creatine kinase-MB .53 normal, baseline creatinine,
CrCl, angiographic contrast volume, hematocrit drop and
need for blood transfusion. The only independent pre-
dictors of renal function deterioration were blood trans-
fusion (OR 5 1.55, 95% CI 5 1.27 to 1.91, p , 0.0001),
contrast volume (OR 5 1.003, 95% CI 5 1.001 to 1.006,
p 5 0.01) and left ventricular ejection fraction (OR 5
0.97, 95% CI 5 0.95 to 0.99, p 5 0.02).
Clinical outcome (Fig. 1). The combined (cardiac and
noncardiac) in-hospital mortality in patients with further
renal function deterioration was 14.9% compared with 4.9%
in patients with no increase in creatinine (Table 4). The
percentage of deaths from cardiac causes was also elevated in
patients with renal function deterioration. Other complica-
tions (pulmonary edema, gastrointestinal bleeding and need
Abbreviations and Acronyms
CI 5 confidence interval
CrCl 5 creatinine clearance
CRI 5 chronic renal insufficiency
MI 5 myocardial infarction
OR 5 odds ratio
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for blood transfusions) were also more frequent for patients
with renal function deterioration.
Thirty-one patients required hemodialysis during hospi-
talization. Their in-hospital mortality was 22.6%. Four
patients were discharged on chronic dialysis. The cumula-
tive one-year mortality was significantly higher in patients
with renal function deterioration (37.7% vs. 19.4%, p 5
0.001, Table 5 and Fig. 2)—35.4% for those who did not
require dialysis and 45.2% for those who required dialysis.
Of the 17 patients who required in-hospital dialysis and
who were alive at one year, 3 required chronic dialysis.
When the one-year mortality was compared with regard
to the percent increase in creatinine, there was a noticeable
difference in patients with a 25% increase or greater (Fig. 3).
Myocardial infarction and revascularization events were
similar in both groups.
Predictors of mortality. We separated the two groups into
those patients with and those patients without diabetes (Fig.
4). There was no difference in long-term survival between
diabetic patients versus patients who were not diabetic with
no increase in creatinine or between diabetic patients versus
patients who were not diabetic with a further deterioration
in renal function.
The following variables were entered into a multivariate
model predicting death during the follow-up period: age,
male gender, diabetes mellitus, baseline CrCl, left ventric-
ular ejection fraction, left main and vein graft lesion loca-
tion, stent deployment, final minimum lumen diameter,
creatine kinase-MB release, in-hospital dialysis, contrast
volume, creatinine elevation, hematocrit drop and blood
transfusion. Independent predictors of death were creatinine
elevation (OR 5 3.86, 95% CI 5 1.96 to 7.58, p 5 0.0001),
age (OR 5 1.05, 95% CI 5 1.05 to 1.09, p 5 0.03) and vein
graft lesion location (OR 5 1.55, 95% CI 5 0.95 to 2.52,
p 5 0.08).
DISCUSSION
Patients with baseline azotemia and postangioplasty deteri-
oration in renal function had worse short-term and long-
term outcomes compared with patients who did not. These
patients had significant comorbidities (Table 1) and a
significant increase in most in-hospital adverse events:
death, non-Q-wave MI, pulmonary edema and bleeding. At
one-year follow-up, mortality rates were high for both
groups, but especially for patients with deterioration in renal
function (47.7%). Using multivariate analysis, creatinine
elevation, advanced patient age and vein graft lesion location
were independent predictors of death in these patients.
Renal function deterioration postcontrast. Renal func-
tion deterioration after exposure to radiographic contrast
agents is common in patients with impaired renal function
(1,2). Diabetes mellitus is one of the strongest predictors of
acute renal failure after coronary intervention (6). In a study
of patients with diabetic nephropathy and azotemia who
underwent prerenal transplant coronary angiography, 50%
had a serum creatinine increase .25%, and 12% required
dialysis within a week (4). This was not substantiated in this
study. Other reported risk factors include chronic renal
insufficiency; dehydration; ionic, high osmolar contrast
agents and congestive heart failure (14–17).
The renal function deterioration is an important predictor
Table 1. Baseline Clinical Characteristics in Patients With Versus Without Postprocedural
Creatinine Elevation
Group 1
Increase in
Creatinine >25%
(n 5 161)
Group 2
No Increase
in Creatinine
(n 5 278) p Value
Age (yr) 70 6 10 70 6 10 0.642
Men (%) 68.1 71.2 0.544
Accelerated angina (%) 32.9 35.8 0.748
Post-MI angina (%) 17.7 17.9 0.620
Prior MI (%) 59.4 62.0 0.611
Prior CABG (%) 52.4 55.2 0.711
Prior PTCA (%) 31.9 38.3 0.248
Hypertension (%) 82.5 76.1 0.170
Diabetes mellitus (%) 55.4 42.4 0.061
Insulin dependent (%) 25.9 17.8 0.074
Hyperlipidemia (%) 51.8 56.1 0.352
LVEF 0.35 6 0.14 0.42 6 0.14 ,0.001
CABG 5 coronary artery bypass graft surgery; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty.
Table 2. Baseline and Postprocedural Laboratory Values
Group 1 Group 2 p Value
Baseline serum creatinine
(mg/dL)
2.8 6 1.3 3.2 6 2.6 0.003
Baseline CrCl (ml/min) 2.8 6 1.3 3.2 6 2.6 0.205
(1.9–9.1) (1.9–15.8)
Contrast volume (ml) 261 6 148 214 6 98 0.002
(50–1,000) (50–560)
Peak serum creatinine
(mg/dL)
5.10 6 2.3 3.18 6 2.6 ,0.001
Serum creatinine @
discharge (mg/dL)
3.56 6 1.5 2.24 6 1.0 ,0.001
Body surface area (m2) 1.88 6 0.2 1.90 6 0.2 0.306
CrCl 5 creatinine clearance.
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of in-hospital mortality. Rich et al. (2) reported 183
patients $ 70 years of age undergoing cardiac catheteriza-
tion—including patients with prior renal insufficiency
(mean serum creatinine 1.3 6 0.7 mg/dL); 21/183 patients
(11.5%) developed progressive renal dysfunction (serum
creatinine elevation .0.5 mg/dL), which persisted in five of
them (24%). The overall in-hospital mortality was 7.1% to
14.3% for those who developed progressive renal dysfunc-
tion and 6.2% for those who did not. Levy et al. (10)
reported 183 patients who developed contrast-mediated
renal dysfunction and compared these index patients against
174 “controls” matched for age and baseline serum creati-
nine. The in-hospital mortality was 34% in the index cases
versus 7% in the control population.
A 25% increase in creatinine was the typical definition of
renal function deterioration used in the preceding studies.
The use of this “cutoff” as a predictor of cumulative
mortality was substantiated in this study (Fig. 3).
Patients with azotemia were at a higher risk for
bleeding complications and required blood transfusions
more often. Bleeding, hypovolemia and hypotension may
lead to further deterioration in renal function. In this
study blood transfusion, but not bleeding, was an inde-
pendent predictor of creatinine elevation, nor was it a
predictor of mortality.
Dialysis. The risk of emergency dialysis after radiographic
contrast ranges up to 12% in patients with baseline serum
creatinine levels above 1.4 mg/dL (18). In-hospital mortal-
ity rates for patients who require emergency dialysis have
been reported to be as high as 62%; conversely, in patients
who developed renal failure but did not require dialysis, the
mortality rate was lower (31%) (18). In one report of 132
critically ill patients in the intensive care unit who developed
Figure 1. A flow diagram detailing the mortality of 439 patients with pre-existing renal insufficiency undergoing percutaneous coronary intervention.
Table 3. Angiographic Findings
Group 1 Group 2 p Value
Lesion location
Left main (%) 8.2 7.3 0.571
Left anterior descending (%) 24.6 29.3 0.417
Left circumflex (%) 14.6 21.5 0.239
Right coronary (%) 15.5 18.9 0.109
Saphenous vein graft (%) 37.3 23.0 0.004
Ostial location (%) 29.1 23.3 0.229
Calcification (%) 29.4 34.4 0.463
TIMI 3 flow (%) 90.2 90.0 0.821
Reference diameter (mm) 3.00 6 1.0 2.68 6 0.7 0.011
Preprocedural MLD (mm) 0.92 6 0.6 0.89 6 0.5 0.876
Preprocedural DS (%) 69 6 16 66 6 21 0.142
Final MLD (mm) 2.54 6 0.9 2.15 6 0.9 0.002
Final DS (%) 17 6 17 22 6 21 0.058
DS 5 diameter stenosis; MLD 5 minimal lumen diameter; TIMI 5 Thrombolysis
in Myocardial Infarction trial.
Table 4. In-hospital Outcome
Group 1 Group 2 p Value
Angiographic success (%) 96.8 97.8 0.495
Death (%) 14.9 4.9 0.001
Cardiac death (%) 9.6 3.3 0.003
Q-wave MI (%) 0.0 1.3 0.303
Non-Q-wave MI (%) 28.7 15.9 0.007
Emergency/urgent CABG (%) 2.4 1.0 0.697
Repeat PTCA (%) 5.4 3.9 1.0
Pulmonary edema (%) 28.5 7.9 0.001
GI bleeding (%) 11.3 4.8 0.024
Blood transfusion (.2 U) (%) 42.8 15.9 0.001
CABG 5 coronary artery bypass graft surgery; GI 5 gastrointestinal; MI 5
myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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acute renal failure and required dialysis, the in-hospital
mortality rate was 70%; of those who were discharged, 33%
were dialysis dependent (19).
Using a definition similar to the current study (a 25%
increase in creatinine), McCullough et al. (6) reported an
incidence of acute renal failure after coronary interventions
of 14.5%. The in-hospital mortality rate for these patients
was 7.1 but increased to 35.7% for patients who required
dialysis.
Whether these patients, especially patients who require
dialysis, die from renal failure itself or from the underlying
conditions is an unresolved issue (18). Analysis of our data
and data from other studies suggests that comorbidities
alone do not account for the increased mortality. When the
effect of comorbidity was controlled in a multivariate model
in this study, renal deterioration still predicted increased
mortality.
Potential mechanisms. At least four mechanisms have
been implicated in contrast-induced nephropathy. After
radiographic contrast exposure, there is a brief period of
vasodilation followed by renal vasoconstriction leading to
intense, but transient, reduction in renal blood flow, direct
toxicity to renal tubular epithelium, tubular obstruction by
protein precipitates and complement activation (14).
Recent works have suggested that endothelin, a potent
endogenous vasoconstrictor, may be an important contrib-
utor to ischemic damage to the kidneys in certain circum-
stances and has been proposed as one of the potential
mediators of renal vascular vasoconstriction. The exposure
to large volumes of contrast material is associated with
increased levels of circulating endothelin both in animal
models and in humans. This is even more exaggerated in
diabetic patients or patients with CRI (20,21). The simul-
taneous release of various endogenous renal vasodilators—
such as atrial natriuretic peptide, nitric oxide and prosta-
glandins E2 and I2—may play an important role in
counterbalancing the vasoconstrictive effects of endothelin
by enhancing the glomerular filtration rate and urinary
output (22).
Prevention. Several measures have been tried in an attempt
to prevent or reduce further renal function deterioration
after contrast exposure: hydration, furosemide, mannitol,
calcium channel-blockers, dopamine, atrial natriuretic pep-
tide, endothelin inhibitors and theophylline (23–25). Hy-
dration with 0.45% saline and the use of low osmolality
contrast media have been shown to provide some protection
(24,26). Recent reports have also suggested that forced
diuresis with furosemide, mannitol and intravenous 0.45%
saline may have a beneficial effect (27).
Study limitations. The current report is a retrospective
analysis, and, therefore, the results and conclusions are
subject to the limitations inherent in all such reports.
location and poor left ventricular ejection fraction. In
Figure 2. Kaplan-Meier estimates of survival for group 1 (renal function deterioration, solid line) versus group 2 (no increase in serum creatinine, dashed
line, p , 0.001).
Table 5. Cumulative One-year Outcome
Group 1 Group 2 p Value
Death (%) 37.7 19.4 0.001
Myocardial infarction (%) 13.4 12.4 0.661
TLR (%) 21.4 23.6 0.841
TLR PTCA (%) 15.0 18.8 0.845
TLR CABG (%) 8.5 5.9 0.278
CABG 5 coronary artery bypass graft surgery; PTCA 5 percutaneous transluminal
coronary angioplasty; TLR 5 target lesion revascularization.
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addition, this was a high-risk patient population with a
majority of the patients having had previous bypass surgery.
The use of glycoprotein IIb/IIIa inhibitors in this patient
population was ,2%. Serum creatinine was only measured
for 48 h; we may have missed a later increase in creatinine
in some of the 63% of the patients who did not have renal
function deterioration within 48 h of their procedure.
Clinical implications. These data show that in patients
with pre-existing renal insufficiency, renal function deteri-
oration (elevation of serum creatinine above 25% baseline
levels or need for dialysis) after coronary intervention is a
marker for poor in-hospital and long-term outcomes. Pa-
tients who require dialysis after the procedure are especially
prone to a poor clinical outcome, and every measure should
Figure 3. Relation of the percentage increase in serum creatinine to 1-year mortality. There was a significant increase in mortality when the increase in
creatinine was greater than 25% (p , 0.0001).
Figure 4. Kaplan-Meier estimates of survival comparing diabetic patients versus patients who were not diabetic in group 1 (renal function deterioration,
p 5 NS) and diabetic patients versus patients who were not diabetic in group 2 (no increase in serum creatine, p 5 NS). DM 5 diabetes mellitus.
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be taken to avoid such an end point. Even in the era of
modern interventional cardiology and new contrast agents,
the risk of renal injury remains high with important long-
term consequences.
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